FDA's slow approval process is failing terminally ill children who need experimental treatments
Source: "My son is dying — families like mine can’t afford FDA delays and red tape | Fox News." April 29, 2026. www.foxnews.com
The Gist
A mother whose son is dying from a rare disease argues that the FDA takes too long to approve experimental treatments. She believes families should be allowed to try risky treatments because doing nothing guarantees death, while experimental drugs offer hope.
Conclusion
The FDA must reform its drug approval process to prioritize speed and patient choice for terminally ill children with rare diseases
Premises
- Terminally ill children like the author's son face irreversible decline while waiting for experimental treatments
- Current FDA approval processes subject life-saving therapies to extended review cycles and ignore accelerated pathways
- Families with terminally ill children understand treatment risks better than bureaucrats making decisions from offices
- For terminal patients, doing nothing is always 100% deadly, making any treatment risk worthwhile
- The current system prioritizes bureaucratic caution over the lives of dying children
- FDA leadership promised regulatory flexibility but has repeatedly delayed or restricted treatments
Assumptions
- Experimental treatments offer meaningful hope for terminal rare disease patients
- Parents are capable of making informed risk-benefit decisions for their dying children
- FDA bureaucrats are disconnected from the reality of terminal illness
- Speed of approval is more important than extensive safety testing for terminal patients
- The current regulatory framework can be reformed without abandoning scientific standards